ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patient with chronic myelogenous leukemia (CML)

A. R. Zander, N. Kröger, M. Schleuning, J. Finke, T. Zabelina, D. Beelen, R. Schwerdtfeger, H. Baurmann, M. Bornhäuser, G. Ehninger, A. A. Fauser, M. Kiehl, R. Trenschel, H. D. Ottinger, H. Bertz, J. Berger, H. J. Kolb, U. W. Schaefer

Research output: Contribution to journalArticlepeer-review

54 Scopus citations

Abstract

Matched unrelated donor transplants have an increased risk of severe graft-versus-host disease and transplant-related mortality (TRM). ATG has been introduced to decrease GvHD and to facilitate engraftment. We conducted a retrospective analysis of 333 patients with chronic myelogenous leukemia, who were treated with Fresenius ATG (n = 145, average = 90 mg/kg bw, range 40-90 mg/kg bw) or standard immunosuppression without ATG (n = 188). Both groups were comparable regarding distribution of age, sex, HLA-matched vs mismatched donors. ATG Fresenius led to a faster leukocyte engraftment, decreased the incidence of acute GvHD and TRM (P=0.01 and P=0.03) and led to a significant better overall survival (70 vs 57%, P = 0.03). We concluded that a prospective randomized study is needed to evaluate the definite role of ATG in hemopoietic stem cell transplantation.

Original languageEnglish
Pages (from-to)355-361
Number of pages7
JournalBone Marrow Transplantation
Volume32
Issue number4
DOIs
StatePublished - Aug 2003
Externally publishedYes

Keywords

  • ATG
  • GvHD
  • MuD = Mismatched unrelated donor transplantation

Fingerprint

Dive into the research topics of 'ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patient with chronic myelogenous leukemia (CML)'. Together they form a unique fingerprint.

Cite this